Short answer
MANNKIND CORP (MNKD) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). November 5, 2026 press release announces MannKind’s fiscal-year 2026 results.
MANNKIND CORP 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- November 5, 2026 press release announces MannKind’s fiscal-year 2026 results
- Full financial results and management commentary are in Exhibit 99.1
- Investor focus: annual revenue, profitability, cash position and 2027 outlook in the accompanying release
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $101.9M, up 24%, led by Furoscix $22.4M and commercial product revenue $45.0M, up 102%
- Furoscix ReadyFlow reached approximately 75% of weekly shipments, signaling rapid post-approval adoption and potential Q4 revenue acceleration
- Afrezza prescriptions rose approximately 17% sequentially, with 2,000 pediatric patients treated across all 60 priority institutions
- GAAP net loss $23.2M, or $0.07 per share, as SG&A increased 111% to $61.4M from launch investments
- Cash, equivalents and investments $96.6M, after a $50M private placement funding the $45M Furoscix ReadyFlow CVR payment
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other MANNKIND CORP 8-K filings
Get the next MNKD 8-K as it lands
Follow MNKD for push alerts, or ask the research agent what this filing means.